Table 3.
Inhibition of platelet aggregation (%) over time in Study I and Study II.
| Day | Time (h) | IPA(%) | ||||||
|---|---|---|---|---|---|---|---|---|
| Vicagrel (5 mg; N = 9) | Vicagrel (10 mg; N = 9) | Vicagrel (15 mg; N = 9) | Clopidogrel (75 mg; N = 9) | Placebo (N = 9) | Vicagrel (30 mg/7.5 mg; N = 15) | Vicagrel (30 mg/7.5 mg + aspirin at 100 mg; N = 15) | ||
| 1 | 0 | 0.67 (1.4) | 4.89 (7.3) | 0.89 (2.7) | 1.22 (3.7) | 2.11 (4.2) | 4.9 (10.4) | 9.7 (10.1) |
| 1 | 0.5 | – | – | – | – | – | 22.5 (16.4) | – |
| 1 | 1 | – | – | – | – | – | 50.4 (20.1) | – |
| 1 | 2 | – | – | – | – | – | 64.1 (15.2) | – |
| 1 | 4 | – | – | – | – | – | 62.9 (13.6) | – |
| 1 | 8 | – | – | – | – | – | 62.4 (14.6) | – |
| 1 | 24 | – | – | – | – | – | 53.9 (19.2) | 58.9 (17.3) |
| 3 | 4 | – | – | – | – | – | 69.3 (15.8) | 71.2 (15.0) |
| 4 | 4 | 31.8 (18.8) | 59.7 (18.0) | 84.8 (20.5) | 44.9 (28.7) | 1.9 (5.7) | – | – |
| 5 | 4 | – | – | – | – | – | 68.4 (15.4) | 71.7 (15.6) |
| 8 | 0 | – | – | – | – | – | 53.0 (16.6) | 56.2 (13.7) |
| 8 | 4 | 33.6 (20.5) | 53.1 (18.5) | 82.2 (17.6) | 48.4 (22.1) | 0.0 (0.0) | 65.8 (17.7) | 68.7 (17.1) |
| 8 | 24 | – | – | – | – | – | 58.6 (16.8) | 56.1 (18.3) |
| 8 | 48 | – | – | – | – | – | 39.7 (13.9) | 39.8 (16.0) |
| 8 | 72 | – | – | – | – | – | 26.4 (11.9) | 32.1 (11.7) |
| 8 | 96 | – | – | – | – | – | 19.9 (9.8) | 21.7 (13.3) |
| 8 | 120 | – | – | – | – | – | 15.1 (9.8) | 16.2 (8.5) |
| 8 | 144 | – | – | – | – | – | 11.1 (11.3) | 8.9 (9.3) |
| 8 | 168 | – | – | – | – | – | 10.8 (8.3) | 5.0 (7.6) |
| 10 | 0 | 37.0 (23.3) | 51.0 (22.0) | 73.9 (22.2) | 39.4 (16.7) | 0.4 (1.1) | – | – |
| 10 | 4 | 32.4 (22.2) | 60.7 (18.1) | 79.1 (22.8) | 46.6 (21.2) | 0.0 (0.0) | – | – |
| 10 | 24 | 34.3 (18.8) | 50.0 (20.3) | 66.0 (19.9) | 38.3 (17.9) | 0.0 (0.0) | – | – |
| 10 | 48 | 21.9 (16.6) | 40.6 (22.4) | 53.0 (21.5) | 27.9 (17.2) | 0.8 (1.4) | – | – |
| 10 | 72 | 15.3 (15.6) | 28.0 (12.9) | 39.8 (19.1) | 20.6 (14.2) | 0.8 (1.7) | – | – |
Values are given as the mean (standard deviation).